Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy; Edward V. Loftus

doi:10.1016/j.gtc.2006.09.008

Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

Jagadeshwar G. Reddy, Edward V. Loftus

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article

71 Scopus citations

Abstract

In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

Original language	English (US)
Pages (from-to)	837-855
Number of pages	19
Journal	Gastroenterology Clinics of North America
Volume	35
Issue number	4
DOIs	https://doi.org/10.1016/j.gtc.2006.09.008
State	Published - Dec 1 2006

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1016/j.gtc.2006.09.008

Fingerprint Dive into the research topics of 'Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases'. Together they form a unique fingerprint.

Cite this

Reddy, J. G., & Loftus, E. V. (2006). Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases. Gastroenterology Clinics of North America, 35(4), 837-855. https://doi.org/10.1016/j.gtc.2006.09.008

@article{2d342a83e2ee471c8bc058db38306fd5,

title = "Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases",

abstract = "In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.",

author = "Reddy, {Jagadeshwar G.} and Loftus, {Edward V.}",

year = "2006",

month = dec,

day = "1",

doi = "10.1016/j.gtc.2006.09.008",

language = "English (US)",

volume = "35",

pages = "837--855",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases

AU - Reddy, Jagadeshwar G.

AU - Loftus, Edward V.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

AB - In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol will ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-α therapy is critical in maintaining a proper benefit-to-risk ratio.

UR - http://www.scopus.com/inward/record.url?scp=33751334334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751334334&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2006.09.008

DO - 10.1016/j.gtc.2006.09.008

M3 - Review article

C2 - 17129816

AN - SCOPUS:33751334334

VL - 35

SP - 837

EP - 855

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 4

ER -